Ranolazine

Ranolazine
Clinical data
Trade namesRanexa, Aspruzyo Sprinkle, Corzyna
AHFS/Drugs.comMonograph
MedlinePlusa606015
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability35 to 50%
Protein binding~62%
MetabolismExtensive in liver (CYP3A, CYP2D6) and intestine
Elimination half-life1.4 to 1.9 hours[4]
ExcretionKidney (75%) and fecal (25%)
Identifiers
  • (RS)-N-(2,6-Dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]piperazin-1-yl]acetamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.149.259 Edit this at Wikidata
Chemical and physical data
FormulaC24H33N3O4
Molar mass427.545 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C(Nc1c(cccc1C)C)CN3CCN(CC(O)COc2ccccc2OC)CC3
  • InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29) checkY
  • Key:XKLMZUWKNUAPSZ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain.[5] Typically it is used together with other medications when those are insufficient.[5][6] Therapeutic benefits appear smaller in females than males.[5] It is taken by mouth.[5]

Common side effects include constipation, headache, nausea, and dizziness.[5] Serious side effects may include QT prolongation.[5] Ranolazine is contraindicated (not recommended) in those with liver cirrhosis.[5] How it works is not clear but may involve adenosine triphosphate.[5]

Ranolazine was approved for medical use in the United States in 2006.[5] In 2021, it was the 202nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
  2. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  3. ^ "Summary Basis of Decision (SBD) for Corzyna". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  4. ^ Jerling, M. (2006). Clinical pharmacokinetics of ranolazine. Clinical pharmacokinetics, 45, 469-491.
  5. ^ a b c d e f g h i "Ranolazine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 22 March 2019.
  6. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 210. ISBN 9780857113382.
  7. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  8. ^ "Atomoxetine - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.